scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Nantahala Capital Management LLC

Nantahala Capital Management LLC lifted its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 33.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,000,000 shares of the company's stock after acquiring an additional 250,000 shares during the quarter. Nantahala Capital Management LLC owned 2.00% of scPharmaceuticals worth $3,540,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of SCPH. Northern Trust Corp boosted its stake in scPharmaceuticals by 27.1% during the 4th quarter. Northern Trust Corp now owns 324,226 shares of the company's stock valued at $1,148,000 after acquiring an additional 69,092 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of scPharmaceuticals during the fourth quarter worth about $54,000. Balanced Rock Investment Advisors LLC increased its holdings in scPharmaceuticals by 8.7% in the fourth quarter. Balanced Rock Investment Advisors LLC now owns 70,362 shares of the company's stock valued at $249,000 after buying an additional 5,612 shares during the last quarter. Barclays PLC raised its stake in scPharmaceuticals by 60.8% during the fourth quarter. Barclays PLC now owns 65,361 shares of the company's stock valued at $232,000 after buying an additional 24,717 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in scPharmaceuticals during the 4th quarter worth approximately $318,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SCPH has been the subject of a number of research analyst reports. Maxim Group lowered their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a report on Thursday, March 20th.

scPharmaceuticals Stock Performance

Shares of NASDAQ SCPH traded up $0.07 during mid-day trading on Friday, hitting $2.60. The company had a trading volume of 156,493 shares, compared to its average volume of 356,405. scPharmaceuticals Inc. has a 12 month low of $1.94 and a 12 month high of $5.65. The stock has a market cap of $130.74 million, a price-to-earnings ratio of -1.37 and a beta of 0.38. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm's 50 day simple moving average is $2.74 and its two-hundred day simple moving average is $3.31.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The company had revenue of $12.15 million for the quarter, compared to analysts' expectations of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. As a group, equities research analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.